Primmune Therapeutics' Incubator/Accelerator Round

Primmune Therapeutics raised a round of funding on January 03, 2018. Investors include JLabs.

Primmune Therapeutics is developing an orally administered toll-like receptor 7 (TLR7) agonist for systemic activation of innate immunity.…

Articles about Primmune Therapeutics' Incubator/Accelerator Round: